PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of ESR1 and SCFD2
- 1 June 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (11), 2230-2242
- https://doi.org/10.1158/0008-5472.can-19-3095
Abstract
Endocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer, yet long-term treatment often causes acquired resistance, which results in recurrence and metastasis. Recent studies have revealed that RNA-binding proteins (RBP) are involved in tumorigenesis. Here we demonstrate that PSF/SFPQ is an RBP that potentially predicts poor prognosis of ER-positive breast cancer patients by posttranscriptionally regulating ERα (ESR1) mRNA expression. Strong PSF immunoreactivity correlated with shorter overall survival in ER-positive breast cancer patients. PSF was predominantly expressed in a model of tamoxifen-resistant breast cancer cells, and depletion of PSF attenuated proliferation of cultured cells and xenografted tumors. PSF expression was significantly associated with estrogen signaling. PSF siRNA downregulated ESR1 mRNA by inhibiting nuclear export of the RNA. Integrative analyses of microarray and RNA-immunoprecipitation sequencing also identified SCFD2, TRA2B, and ASPM as targets of PSF. Among the PSF targets, SCFD2 was a poor prognostic indicator of breast cancer and SCFD2 knockdown significantly suppressed breast cancer cell proliferation. Collectively, this study shows that PSF plays a pathophysiological role in ER-positive breast cancer by posttranscriptionaly regulating expression of its target genes such as ESR1 and SCFD2. Overall, PSF and SCFD2 could be potential diagnostic and therapeutic targets for primary and hormone-refractory breast cancers.Other Versions
Funding Information
- Japan Society for the Promotion of Science (15K15353)
- Japan Society for the Promotion of Science (17H04205)
- Japan Society for the Promotion of Science (16K09809)
- Japan Society for the Promotion of Science (17K18061)
- Japan Society for the Promotion of Science (18J00252)
- Innovative Cancer Control (JP18ck0106194)
- Cancer Research And Therapeutic Evolution (JP18cm0106144)
This publication has 56 references indexed in Scilit:
- PTB-Associated Splicing Factor (PSF) Is a PPARγ-Binding Protein and Growth Regulator of Colon Cancer CellsPLOS ONE, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- A Rapid, Extensive, and Transient Transcriptional Response to Estrogen Signaling in Breast Cancer CellsCell, 2011
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patientsBreast Cancer Research and Treatment, 2009
- Involvement of p54(nrb), a PSF partner protein, in DNA double-strand break repair and radioresistanceNucleic Acids Research, 2009
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJCI Insight, 2007
- Functional Analysis of p53 Binding under Differential StressesMolecular and Cellular Biology, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Sly1 protein bound to Golgi syntaxin Sed5p allows assembly and contributes to specificity of SNARE fusion complexesThe Journal of cell biology, 2002